|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cho KR and Shih IeM: Ovarian cancer. Annu
Rev Pathol. 4:287–313. 2009. View Article : Google Scholar :
|
|
3
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Halder G and Johnson RL: Hippo signaling:
Growth control and beyond. Development. 138:9–22. 2011. View Article : Google Scholar :
|
|
5
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lei QY, Zhang H, Zhao B, Zha ZY, Bai F,
Pei XH, Zhao S, Xiong Y and Guan KL: TAZ promotes cell
proliferation and epithelial-mesenchymal transition and is
inhibited by the hippo pathway. Mol Cell Biol. 28:2426–2436. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oka T, Mazack V and Sudol M: Mst2 and Lats
kinases regulate apoptotic function of Yes kinase-associated
protein (YAP). J Biol Chem. 283:27534–27546. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu
J, Lin JD, Wang CY, Chinnaiyan AM, et al: TEAD mediates
YAP-dependent gene induction and growth control. Genes Dev.
22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang H, Liu CY, Zha ZY, Zhao B, Yao J,
Zhao S, Xiong Y, Lei QY and Guan KL: TEAD transcription factors
mediate the function of TAZ in cell growth and
epithelial-mesenchymal transition. J Biol Chem. 284:13355–13362.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chan SW, Lim CJ, Loo LS, Chong YF, Huang C
and Hong W: TEADs mediate nuclear retention of TAZ to promote
oncogenic transformation. J Biol Chem. 284:14347–14358. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shimomura T, Miyamura N, Hata S, Miura R,
Hirayama J and Nishina H: The PDZ-binding motif of Yes-associated
protein is required for its co-activation of TEAD-mediated CTGF
transcription and oncogenic cell transforming activity. Biochem
Biophys Res Commun. 443:917–923. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu
Q, Wang Y, Halder G, Finegold MJ, Lee JS, et al: Hippo signaling is
a potent in vivo growth and tumor suppressor pathway in the
mammalian liver. Proc Natl Acad Sci USA. 107:1437–1442. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Imajo M, Miyatake K, Iimura A, Miyamoto A
and Nishida E: A molecular mechanism that links Hippo signalling to
the inhibition of Wnt/β-catenin signalling. EMBO J. 31:1109–1122.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lai D, Ho KC, Hao Y and Yang X: Taxol
resistance in breast cancer cells is mediated by the hippo pathway
component TAZ and its downstream transcriptional targets Cyr61 and
CTGF. Cancer Res. 71:2728–2738. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jeong W, Kim SB, Sohn BH, Park YY, Park
ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DSL, et al:
Activation of YAP1 is associated with poor prognosis and response
to taxanes in ovarian cancer. Anticancer Res. 34:811–817.
2014.PubMed/NCBI
|
|
16
|
Bartel DP: Bartel. Cell. 136:215–233.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ren D, Wang M, Guo W, Huang S, Wang Z,
Zhao X, Du H, Song L and Peng X: Double-negative feedback loop
between ZEB2 and miR-145 regulates epithelial-mesenchymal
transition and stem cell properties in prostate cancer cells. Cell
Tissue Res. 358:763–778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ren D, Wang M, Guo W, Zhao X, Tu X, Huang
S, Zou X and Peng X: Wild-type p53 suppresses the
epithelial-mesenchymal transition and stemness in PC-3 prostate
cancer cells by modulating miR-145. Int J Oncol. 42:1473–1481.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang X, Liu J, Zang D, Wu S, Liu A, Zhu
J, Wu G, Li J and Jiang L: Upregulation of miR-572
transcriptionally suppresses SOCS1 and p21 and contributes to human
ovarian cancer progression. Oncotarget. 6:15180–15193.
2015.PubMed/NCBI
|
|
20
|
Ren D, Yang Q, Dai Y, Guo W, Du H, Song L
and Peng X: Oncogenic miR-210 3p promotes prostate cancer cell EMT
and bone metastasis via NF-κB signaling pathway. Mol Cancer.
16:1172017. View Article : Google Scholar
|
|
21
|
Guo W, Ren D, Chen X, Tu X, Huang S, Wang
M, Song L, Zou X and Peng X: HEF1 promotes epithelial mesenchymal
transition and bone invasion in prostate cancer under the
regulation of microRNA-145. J Cell Biochem. 114:1606–1615. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dai Y, Ren D, Yang Q, Cui Y, Guo W, Lai Y,
Du H, Lin C, Li J, Song L, et al: The TGF-β signalling negative
regulator PICK1 represses prostate cancer metastasis to bone. Br J
Cancer. 117:685–694. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bitarte N, Bandres E, Boni V, Zarate R,
Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM,
Fortes P, et al: MicroRNA-451 is involved in the self-renewal,
tumorigenicity, and chemoresistance of colorectal cancer stem
cells. Stem Cells. 29:1661–1671. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Talmon G and Wang J: MicroRNA-587
antagonizes 5-FU-induced apoptosis and confers drug resistance by
regulating PPP2R1B expression in colorectal cancer. Cell Death Dis.
6:e18452015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ren D, Lin B, Zhang X, Peng Y, Ye Z, Ma Y,
Liang Y, Cao L, Li X, Li R, et al: Maintenance of cancer stemness
by miR-196b-5p contributes to chemoresistance of colorectal cancer
cells via activating STAT3 signaling pathway. Oncotarget.
8:49807–49823. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang M, Ren D, Guo W, Huang S, Wang Z, Li
Q, Du H, Song L and Peng X: N-cadherin promotes
epithelial-mesenchymal transition and cancer stem cell-like traits
via ErbB signaling in prostate cancer cells. Int J Oncol.
48:595–606. 2016. View Article : Google Scholar
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
29
|
Hahn WC, Dessain SK, Brooks MW, King JE,
Elenbaas B, Sabatini DM, DeCaprio JA and Weinberg RA: Enumeration
of the simian virus 40 early region elements necessary for human
cell transformation. Mol Cell Biol. 22:2111–2123. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang X, Ren D, Guo L, Wang L, Wu S, Lin
C, Ye L, Zhu J, Li J, Song L, et al: Thymosin beta 10 is a key
regulator of tumorigenesis and metastasis and a novel serum marker
in breast cancer. Breast Cancer Res. 19:152017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang X, Zhang L, Lin B, Chai X, Li R,
Liao Y, Deng X, Liu Q, Yang W, Cai Y, et al: Phospholipid
Phosphatase 4 promotes proliferation and tumorigenesis, and
activates Ca2+-permeable Cationic Channel in lung carcinoma cells.
Mol Cancer. 16:1472017. View Article : Google Scholar :
|
|
32
|
Li X, Liu F, Lin B, Luo H, Liu M, Wu J, Li
C, Li R, Zhang X, Zhou K, et al: miR-150 inhibits proliferation and
tumorigenicity via retarding G1/S phase transition in
nasopharyngeal carcinoma. Int J Oncol. Mar 10–2017.Epub ahead of
print. View Article : Google Scholar
|
|
33
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
eLife. 4:42015. View Article : Google Scholar
|
|
34
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The microRNA.org resource: Targets and expression.
Nucleic Acids Res. 36:Database. D149–D153. 2008. View Article : Google Scholar :
|
|
35
|
Cordenonsi M, Zanconato F, Azzolin L,
Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR,
Poletti A, et al: The Hippo transducer TAZ confers cancer stem
cell-related traits on breast cancer cells. Cell. 147:759–772.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang J, Wu S, Barrera J, Matthews K and
Pan D: The Hippo signaling pathway coordinately regulates cell
proliferation and apoptosis by inactivating Yorkie, the Drosophila
homolog of YAP. Cell. 122:421–434. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu CY, Zha ZY, Zhou X, Zhang H, Huang W,
Zhao D, Li T, Chan SW, Lim CJ, Hong W, et al: The hippo tumor
pathway promotes TAZ degradation by phosphorylating a phosphodegron
and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem.
285:37159–37169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huo X, Zhang Q, Liu AM, Tang C, Gong Y,
Bian J, Luk JM, Xu Z and Chen J: Overexpression of Yes-associated
protein confers doxorubicin resistance in hepatocellullar
carcinoma. Oncol Rep. 29:840–846. 2013. View Article : Google Scholar
|
|
39
|
Touil Y, Igoudjil W, Corvaisier M, Dessein
AF, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G,
et al: Colon cancer cells escape 5FU chemotherapy-induced cell
death by entering stemness and quiescence associated with the
c-Yes/YAP axis. Clin Cancer Res. 20:837–846. 2014. View Article : Google Scholar
|
|
40
|
Ren A, Yan G, You B and Sun J:
Down-regulation of mammalian sterile 20-like kinase 1 by heat shock
protein 70 mediates cisplatin resistance in prostate cancer cells.
Cancer Res. 68:2266–2274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen M, Wang M, Xu S, Guo X and Jiang J:
Upregulation of miR-181c contributes to chemoresistance in
pancreatic cancer by inactivating the Hippo signaling pathway.
Oncotarget. 6:44466–44479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fan Q, Cheng Y, Chang HM, Deguchi M, Hsueh
AJ and Leung PCK: Sphingosine-1-phosphate promotes ovarian cancer
cell proliferation by disrupting Hippo signaling. Oncotarget.
8:27166–27176. 2017.PubMed/NCBI
|
|
43
|
He C, Lv X, Hua G, Lele SM, Remmenga S,
Dong J, Davis JS and Wang C: YAP forms autocrine loops with the
ERBB pathway to regulate ovarian cancer initiation and progression.
Oncogene. 34:6040–6054. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang X, George J, Deb S, Degoutin JL,
Takano EA, Fox SB and Bowtell DD: The Hippo pathway transcriptional
co-activator, YAP, is an ovarian cancer oncogene. Oncogene.
30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hall CA, Wang R, Miao J, Oliva E, Shen X,
Wheeler T, Hilsenbeck SG, Orsulic S and Goode S: Hippo pathway
effector Yap is an ovarian cancer oncogene. Cancer Res.
70:8517–8525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang Y and Lai ZC: Mob as tumor
suppressor is regulated by bantam microRNA through a feedback loop
for tissue growth control. Biochem Biophys Res Commun. 439:438–442.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lin CW, Chang YL, Chang YC, Lin JC, Chen
CC, Pan SH, Wu CT, Chen HY, Yang SC, Hong TM, et al: MicroRNA-135b
promotes lung cancer metastasis by regulating multiple targets in
the Hippo pathway and LZTS1. Nat Commun. 4:18772013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tan G, Cao X, Dai Q, Zhang B, Huang J,
Xiong S, Zhang Y, Chen W, Yang J and Li H: A novel role for
microRNA-129-5p in inhibiting ovarian cancer cell proliferation and
survival via direct suppression of transcriptional co-activators
YAP and TAZ. Oncotarget. 6:8676–8686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhu G, Wang Y, Mijiti M, Wang Z, Wu PF and
Jiafu D: Upregulation of miR-130b enhances stem cell-like phenotype
in glioblastoma by inactivating the Hippo signaling pathway.
Biochem Biophys Res Commun. 465:194–199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lingzi X, Zhihua Y, Xuelian L, Yangwu R,
Haibo Z, Yuxia Z and Baosen Z: Genetic variants in microRNAs
predict non-small cell lung cancer prognosis in Chinese female
population in a prospective cohort study. Oncotarget.
7:83101–83114. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang C, Sturgis EM, Chen X, Zheng H, Wei Q
and Li G: Pre-miRNA variants as predictors of clinical outcome in
patients with squamous cell carcinomas of the nonoropharynx.
Oncotarget. 7:26444–26453. 2016.PubMed/NCBI
|
|
52
|
Zhu J, Wang S, Zhang W, Qiu J, Shan Y,
Yang D and Shen B: Screening key microRNAs for castration-resistant
prostate cancer based on miRNA/mRNA functional synergistic network.
Oncotarget. 6:43819–43830. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Luo G, Chao YL, Tang B, Li BS, Xiao YF,
Xie R, Wang SM, Wu YY, Dong H, Liu XD, et al: miR-149 represses
metastasis of hepatocellular carcinoma by targeting
actin-regulatory proteins PPM1F. Oncotarget. 6:37808–37823. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chan SH, Huang WC, Chang JW, Chang KJ, Kuo
WH, Wang MY, Lin KY, Uen YH, Hou MF, Lin CM, et al: MicroRNA-149
targets GIT1 to suppress integrin signaling and breast cancer
metastasis. Oncogene. 33:4496–4507. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Øster B, Linnet L, Christensen LL, Thorsen
K, Ongen H, Dermitzakis ET, Sandoval J, Moran S, Esteller M, Hansen
TF, et al COLOFOL steering group: Non-CpG island promoter
hypomethylation and miR-149 regulate the expression of SRPX2 in
colorectal cancer. Int J Cancer. 132:2303–2315. 2013. View Article : Google Scholar
|
